Table 1.

Patient characteristics of the 27 patients with Crohn’s disease included in the study

Age [years]	Sex	Anti-inflammatory medication	Indication for surgery	MC; age at diagnosis	MC; location of disease	MC; behaviour of disease	Pre-op P-CRP
36	f	prednisolone, mesalazine	stenosis	A2	L3	B2	<10
61	m	mesalazine	stenosis	A3	L1	B2	<10
81	m	none	fistula	A3	L1	B3	17
44	f	none	stenosis	A1	L3	B2	<10
39	f	none	stenosis	A2	L3	B2	<10
19	m	budenoside	stenosis	A2	L3	B2	<10
49	m	none	stenosis	A2	L3	B3	13
51	f	prednisolone, azathioprine	stenosis	A2	L3	B2	<10
36	f	budenoside	ileitis, stenosis	A2	L3	B2	<10
71	m	none	stenosis	A3	L3	B2	<10
68	m	prednisolone	stenosis	A3	L1	B2	<10
18	m	sulfasalazine, azathioprine	stenosis	A1	L3	B2	52
42	f	certolizumab	stenosis	A2	L3	B2	<10
39	f	budenoside	stenosis	A2	L1	B2	10
49	m	monoclonal antibody	stenosis	A2	L2	B3	<10
61	m	mesalazine	stenosis	A3	L1	B2	<10
68	m	prednisolone	stenosis	A3	L1	B2	<10
73	f	adalimumab	stenosis	A3	L1	B2	12
36	f	prednisolone, mesalazine	stenosis	A2	L3	B2	<10
71	m	none	stenosis	A3	L1	B2	<10
69	m	mesalazine, prednisolone	stenosis, cecal infl.	A2	L1	B2	<10
45	m	methotrexate, mesalazine	ileocolic resection	A2	L3	B2	<10
22	m	infliximab	ileocolic resection	A2	L1	B3	<10
74	f	none	ileocolic resection	A3	L1	B2	12
53	m	enteral nutrition	ileocolic resection	A2	L3	B3	<10
51	m	none	ileocolic resection	A2	L1	B2	<10
61	f	prednisolone	ileocolic resection	A2	L3	B2	12

MC= Montreal Classification; A1: <16; A2: 16–40; A3: >40; L1: ileum; L2: colon; L3: ileum and colon; B2: strictures; B3: perforations; Pre-op P-CRP: pre-operative plasma C-reactive protein.